Comparison of the survival-promoting effects of CNF1 and TMZ in the GL261 glioma model. (A) Experimental protocol. Tumor induction by GL261 cells was either followed by a single intracerebral injection of CNF1/vehicle at day 5 (top) or by minipump delivery of TMZ from day 5 to day 12 (bottom). (B) Kaplan-Meier survival curves for animals implanted with GL261 cells. Compared to vehicle-infused mice (black line), CNF1 (green) and TMZ treatment (red) significantly increased survival (log Rank test followed by Holm-Sidak test, p < 0.05).